Jaguar Health (NASDAQ:JAGX) Trading Up 17.8%

Jaguar Health, Inc. (NASDAQ:JAGX)’s share price rose 17.8% during trading on Thursday . The stock traded as high as $1.00 and last traded at $0.82. Approximately 141,728,609 shares changed hands during mid-day trading, an increase of 1,185% from the average daily volume of 11,029,066 shares. The stock had previously closed at $0.69.

Separately, ValuEngine downgraded Jaguar Health from a “buy” rating to a “hold” rating in a research note on Wednesday, December 23rd.

The stock has a market cap of $65.67 million, a PE ratio of -0.12 and a beta of 1.48. The firm has a 50-day simple moving average of $0.38 and a 200-day simple moving average of $0.43. The company has a quick ratio of 0.33, a current ratio of 0.42 and a debt-to-equity ratio of 1.26.

Jaguar Health (NASDAQ:JAGX) last posted its earnings results on Sunday, November 15th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.10). The company had revenue of $2.77 million for the quarter. Jaguar Health had a negative return on equity of 659.73% and a negative net margin of 372.81%. On average, research analysts expect that Jaguar Health, Inc. will post -0.69 earnings per share for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Two Sigma Advisers LP bought a new position in Jaguar Health in the second quarter valued at $25,000. Wedbush Securities Inc. bought a new position in shares of Jaguar Health during the third quarter valued at about $33,000. Finally, Virtu Financial LLC grew its stake in shares of Jaguar Health by 560.8% during the third quarter. Virtu Financial LLC now owns 393,390 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 333,861 shares during the last quarter. 0.65% of the stock is currently owned by institutional investors and hedge funds.

About Jaguar Health (NASDAQ:JAGX)

Jaguar Health, Inc, a commercial-stage pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. It operates through two reportable segments, Human Health and Animal Health. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals.

Further Reading: What is meant by a buy rating?

Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with's FREE daily email newsletter.